Current Challenges in Cancer Immunotherapy: Multimodal Approaches to Improve Efficacy and Patient Response Rates

被引:198
作者
Sambi, Manpreet [1 ]
Bagheri, Leila [1 ]
Szewczuk, Myron R. [1 ]
机构
[1] Queens Univ, Dept Biomed & Mol Sci, Kingston, ON, Canada
关键词
SELF-ASSEMBLY NANOPARTICLES; REGULATORY T-CELLS; ZOLEDRONIC ACID; BREAST-CANCER; IMMUNE-SYSTEM; RESISTANCE; DELIVERY; THERAPY; CHECKPOINT; PREBIOTICS;
D O I
10.1155/2019/4508794
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cancer immunotherapy is a promising innovative treatment for many forms of cancer, particularly melanoma. Although immunotherapy has been shown to be efficacious, patient response rates vary and, more often than not, only a small subset of the patients within a large cohort respond favourably to the treatment. This issue is particularly concerning and becomes a challenge of immunotherapy to improve the effectiveness and patient response rates. Here, we review the specific types of available immunotherapy options, their proposed mechanism(s) of action, and the reasons why the patient response to this treatment is variable. The potential favourable options to improve response rates to immunotherapy will be discussed with an emphasis on adopting a multimodal approach on the novel role that the gut microbiota may play in modulating the efficacy of cancer immunotherapy.
引用
收藏
页数:12
相关论文
共 63 条
[1]   Cancer immunotherapies, their safety and toxicity [J].
Alatrash, Gheath ;
Jakher, Haroon ;
Stafford, Patricia D. ;
Mittendorf, Elizabeth A. .
EXPERT OPINION ON DRUG SAFETY, 2013, 12 (05) :631-645
[2]   Gut bacteria in health and disease: a survey on the interface between intestinal microbiology and colorectal cancer [J].
Boleij, Annemarie ;
Tjalsma, Harold .
BIOLOGICAL REVIEWS, 2012, 87 (03) :701-730
[3]   CAR T cell therapy: inroads to response and resistance [J].
Brown, Christine E. ;
Mackall, Crystal L. .
NATURE REVIEWS IMMUNOLOGY, 2019, 19 (02) :73-74
[4]   Prebiotics and the Health Benefits of Fiber: Current Regulatory Status, Future Research, and Goals [J].
Brownawell, Amy M. ;
Caers, Wim ;
Gibson, Glenn R. ;
Kendall, Cyril W. C. ;
Lewis, Kara D. ;
Ringel, Yehuda ;
Slavin, Joanne L. .
JOURNAL OF NUTRITION, 2012, 142 (05) :962-974
[5]   Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial [J].
Buzdar, Aman U. ;
Suman, Vera J. ;
Meric-Bernstam, Funda ;
Leitch, A. Marilyn ;
Ellis, Matthew J. ;
Boughey, Judy C. ;
Unzeitig, Gary ;
Royce, Melanie ;
McCall, Linda M. ;
Ewer, Michael S. ;
Hunt, Kelly K. .
LANCET ONCOLOGY, 2013, 14 (13) :1317-1325
[6]   Zoledronic acid: an unending tale for an antiresorptive agent [J].
Caraglia, Michele ;
Marra, Monica ;
Naviglio, Silvio ;
Botti, Gerardo ;
Addeo, Raffaele ;
Abbruzzese, Alberto .
EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (01) :141-154
[7]   The immune system and the gut microbiota: friends or foes? [J].
Cerf-Bensussan, Nadine ;
Gaboriau-Routhiau, Valerie .
NATURE REVIEWS IMMUNOLOGY, 2010, 10 (10) :735-744
[8]   A New Era in Cancer Immunotherapy: Discovering Novel Targets and Reprogramming the Immune System [J].
Chiriva-Internati, Maurizio ;
Bot, Adrian .
INTERNATIONAL REVIEWS OF IMMUNOLOGY, 2015, 34 (02) :101-103
[9]   Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy [J].
Chowell, Diego ;
Morris, Luc G. T. ;
Grigg, Claud M. ;
Weber, Jeffrey K. ;
Samstein, Robert M. ;
Makarov, Vladimir ;
Kuo, Fengshen ;
Kendall, Sviatoslav M. ;
Requena, David ;
Riaz, Nadeem ;
Greenbaum, Benjamin ;
Carroll, James ;
Garon, Edward ;
Hyman, David M. ;
Zehir, Ahmet ;
Solit, David ;
Berger, Michael ;
Zhou, Ruhong ;
Rizvi, Naiyer A. ;
Chan, Timothy A. .
SCIENCE, 2018, 359 (6375) :582-+
[10]   The Impact of Diet and Lifestyle on Gut Microbiota and Human Health [J].
Conlon, Michael A. ;
Bird, Anthony R. .
NUTRIENTS, 2015, 7 (01) :17-44